US9649364 — Methods for producing stable therapeutic formulations in aprotic polar solvents
Method of Use · Assigned to Xeris Pharmaceuticals Inc · Expires 2036-04-22 · 10y remaining
What this patent protects
This patent protects methods for making stable formulations of therapeutic agents, such as Glucagen, in certain solvents with added stabilizing excipients.
USPTO Abstract
Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
Drugs covered by this patent
- Glucagen (GLUCAGON) · Xeris
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2742 |
— | Glucagen |
U-2742 |
— | Glucagen |
U-2742 |
— | Glucagen |
U-2742 |
— | Glucagen |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.